Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide analysis of differential gene expression after treatment of the PLCε inhibitor U73122 in colorectal CD110+TICs

ABSTRACT: Analysis of PLCε-regulation of tyrosine metabolism at gene expression level. The hypothesis tested in the present study was that the PLCε pathway-directed transcriptional control play a key role for metabolic reprogramming in CD110+TICs after Kras extinction. Results provide important information of the response of colorectal CD110+TICs to inhibition of the PLCε pathway, such as specific stress-responsive genes, up- or down-regulated specific anabolic/catabolic cellular functions.

ORGANISM(S): Mus musculus

PROVIDER: GSE75472 | GEO | 2015/12/01

SECONDARY ACCESSION(S): PRJNA304380

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer

Project description:Activating KRAS mutations (KRAS*) in pancreatic ductal adenocarcinoma (PDAC) drive anabolic metabolism and support tumor maintenance. KRAS* inhibitors show initial anti-tumor activity followed by recurrence due to cancer cell intrinsic and immune mediated paracrine mechanisms. Here, we explored the potential role of cancer associated fibroblasts (CAFs) in enabling KRAS* bypass and identified CAF-derived NRG1 activation of cancer cell ERBB2/ERBB3 receptor tyrosine kinases as a mechanism by which KRAS* independent growth is supported. Genetic extinction or pharmacological inhibition of KRAS* resulted in upregulation of ERBB2 and ERBB3 expression in human and murine models, which prompted cancer cell utilization of CAF-derived NRG1 as a survival factor. Genetic depletion or pharmacological inhibition of ERBB2/ERBB3 or NRG1 abolished KRAS* bypass and synergized with KRASG12D inhibitor in combination treatments in mouse and human PDAC models. Thus, we found that CAFs can contribute to KRAS* inhibitor therapy resistance via paracrine mechanisms, providing an actionable therapeutic strategy to improve the effectiveness of KRAS* inhibitors in PDAC patients.

2023-09-22 | GSE240232 | GEO

Identification of novel genes associated with human glioblastoma (GBM) tumor-initiating cells (TICs)

Project description:Most patients affected by Glioblastoma multiforme (GBM) experience a recurrence of the disease because of the spreading of tumor-initiating cells (TICs) beyond surgical boundary. Unveiling and targeting molecular mechanisms causing this process is a logic goal to impair GBM killing ability. In an orthotopic xenograph model, we have noticed that GBM TICs isolated from several patients may fall into two classes of invasive behavior: nodular or diffuse. In order to identify genes responsible for the diffusive type of invasion, we have compared by genome expression analysis, cultured GBM TICs belonging to the two classes. This analysis allowed us to identify a small group of regulated genes in the diffusive type of GBM TICs. The gene ontology process of cell adhesion and the localization of the gene product functions to the plasmamembrane resulted significantly associated to this gene set. Real time RT-PCR and immunofluorescence analyses performed for a selected subgroup of regulated genes/gene products confirmed the results obtained by the expression analysis. Some of the genes that we found upregulated in our screening were already proven to be involved in Glioma cell invasion supporting our study. However, we have also identified genes that were not previously implicated in this process. To assess whether these are required to sustain TICs GBM invasion, we silenced a subset of them and evaluated in Boyden chamber the invasive ability of the cells. Our study provides novel target genes to be evaluated for the inhibition of GBM diffusion within the SNC.

2012-09-11 | GSE16805 | GEO

Identification of novel genes associated with human glioblastoma (GBM) tumor-initiating cells (TICs)

2012-09-11 | E-GEOD-16805 | biostudies-arrayexpress

Expression data from highly purified MMTV-Neu Tumor Initiating Cells (TICs) and the non-TIC CD24- fraction

Project description:The cancer stem cell model maintains that tumors are organized in a hierarchy driven by tumor initiating cells (TICs), and that patient survival inversely correlates with TIC gene expression. Here we generated a prognostic signature for HER2+ breast cancer from TICs purified from MMTV-Her2/Neu mammary tumors. TICs from this model, identified as Lin-:CD24+:JAG1- at a frequency of 2-5% by serial and single cell transplantation assays, showed elevated expression of proliferation genes and low expression of differentiation genes (compared to non-TIC fraction CD24- of the same tumor). We used microarrays to detect differentially expressed genes in the TIC fraction compared to the non-TIC fraction of the same tumor

2011-05-28 | GSE29590 | GEO

RNAseq data comparing iKPC PDAC tumors with KRAS* expression (ON) and KRAS extinction (OFF)

Project description:KRAS* is required for PDAC tumor mantainence. To dissect the molecular mechanisms that regulated by KRAS* in PDAC tumors, we conducted RNA-seq analysis of KRAS*-expressing iKPC PDAC tumors and iKPC tumors after KRAS* extinction for 24 hours.

2020-04-27 | GSE149129 | GEO

RNA sequencing for tumor-initiating stem-like cells (TICs) treated with all-trans retinoic acid (ATRA) and suberoylanilide hydroxamic acid (SAHA)

Project description:TIC population plays a vital role for tumor recurrence and therapy resistnace. In this study, we identified the drug combination of ATRA and SAHA can specifically target TICs in vitro and in vivo. By conducting RNA sequencing and genome-wide transcriptome analysis, we comprehesively illustrate that the combination treatment epigenetically regulates TICs.

2019-12-31 | GSE78139 | GEO

Selective Akt inhibition by MK-2206 eleminates colorectal cancer-initiating stem cells

Project description:To identify the regulatory mechanisms and signalling pathways involved in colorectal cancer (CRC) development, we compared the transcriptome of patient-derived tumor-initiating cells (TICs) with their normal stem cell counterparts of the same patient. This study demonstrates the relevance of AKT-signalling in colonic TIC proliferation and survival. Functional testing uncovered the selective AKT-inhibitor MK-2206 as a potential therapeutic for TIC-directed therapy in CRC. Gene expression profiling of tumor and normal tissues from 5 patients.

2016-07-06 | E-GEOD-70018 | biostudies-arrayexpress

Differentially expressed genes in iKRAS tumor treated with Trametinib or Kras extinction

Project description:To identify the differentially expressed gene in ikras tumors treated with Trametinib or Kras extinction.

2021-06-07 | GSE176241 | GEO

Expression data from highly purified MMTV-Neu Tumor Initiating Cells (TICs) and the non-TIC CD24- fraction

2011-05-28 | E-GEOD-29590 | biostudies-arrayexpress

Selective Akt inhibition by MK-2206 eleminates colorectal cancer-initiating stem cells

2016-07-06 | GSE70018 | GEO